$0.70
6.06% today
Nasdaq, May 12, 03:50 pm CET
ISIN
US72941H4002
Symbol
PSTV
Sector
Industry

Plus Therapeutics Inc Stock price

$0.66
-0.18 21.41% 1M
-0.53 44.54% 6M
-0.49 42.61% YTD
-1.58 70.54% 1Y
-6.62 90.93% 3Y
-24.09 97.33% 5Y
-79,975.59 100.00% 10Y
Nasdaq, Closing price Fri, May 09 2025
+0.04 6.45%
ISIN
US72941H4002
Symbol
PSTV
Sector
Industry

Key metrics

Market capitalization $11.22m
Enterprise Value $10.98m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.89
P/S ratio (TTM) P/S ratio 1.93
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 18.54%
Revenue (TTM) Revenue $5.82m
EBIT (operating result TTM) EBIT $-14.70m
Free Cash Flow (TTM) Free Cash Flow $-10.70m
Cash position $3.61m
EPS (TTM) EPS $-2.06
P/E forward negative
P/S forward 1.73
EV/Sales forward 1.69
Short interest 12.32%
Show more

Is Plus Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

Plus Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Plus Therapeutics Inc forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a Plus Therapeutics Inc forecast:

Buy
75%
Hold
25%

Financial data from Plus Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
5.82 5.82
19% 19%
100%
- Direct Costs 0.85 0.85
13% 13%
15%
4.97 4.97
19% 19%
85%
- Selling and Administrative Expenses 8.24 8.24
17% 17%
142%
- Research and Development Expense 11 11
9% 9%
182%
-14 -14
10% 10%
-238%
- Depreciation and Amortization 0.85 0.85
13% 13%
15%
EBIT (Operating Income) EBIT -15 -15
10% 10%
-252%
Net Profit -13 -13
3% 3%
-223%

In millions USD.

Don't miss a Thing! We will send you all news about Plus Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Plus Therapeutics Inc Stock News

Neutral
GlobeNewsWire
4 days ago
HOUSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces that it will participate in the D. Boral Capital Inaugural Global Conference.
Neutral
GlobeNewsWire
19 days ago
HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the appointment of Kyle Guse, J.D., M.B.A. to the Company's Board of Directors where he will serve as chair of the Audit Committee ...
Neutral
GlobeNewsWire
27 days ago
New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ New abstract published ahead of the Nuclear Medicine and Neurooncology Conference shows promise for REYOBIQ
More Plus Therapeutics Inc News

Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Head office United States
CEO Marc Hedrick
Employees 21
Founded 1996
Website www.plustherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today